Cibc Bancorp Usa Inc. Supernus Pharmaceuticals, Inc. Transaction History
Cibc Bancorp Usa Inc.
- $80.8 Billion
- Q3 2025
A detailed history of Cibc Bancorp Usa Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cibc Bancorp Usa Inc. holds 5,751 shares of SUPN stock, worth $265,178. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,751Holding current value
$265,178% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
332Shares Held
59.7MCall Options Held
19.1KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$479 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.04MShares$279 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$222 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$138 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.53MShares$117 Million0.14% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.47B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...